Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-γ-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4⁺ T-cell activation

Jeanne M. Soos, Jeffrey I. Krieger, Olaf Stüve, Chelsea L. King, Juan Carlos Patarroyo, Ken Aldape, Karolina Wosik, Anthony J. Slavin, Patricia A. Nelson, Jack P. Antel, Scott S. Zamvil

Neurology & Neurotherapeutics - NE Outside Agreements
Neurology & Neurotherapeutics

Research output: Contribution to journal › Article › peer-review

47 Scopus citations

Fingerprint

Dive into the research topics of 'Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-γ-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4⁺ T-cell activation'. Together they form a unique fingerprint.

Sort by
Weight
Alphabetically

Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-γ-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4+ T-cell activation

Fingerprint

Medicine & Life Sciences

Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-γ-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4⁺ T-cell activation